Effects of denosumab on fracture and bone mineral density by level of kidney function.

PubWeight™: 1.40‹?› | Rank: Top 5%

🔗 View Article (PMID 21491487)

Published in J Bone Miner Res on August 01, 2011

Authors

Sophie A Jamal1, Osten Ljunggren, Catherine Stehman-Breen, Steven Ron Cummings, Michael R McClung, Stefan Goemaere, Peter R Ebeling, Edward Franek, Yu-Ching Yang, Ogo I Egbuna, Steven Boonen, Paul D Miller

Author Affiliations

1: Department of Medicine, University of Toronto, Ontario, Canada. sophie.jamal@utoronto.ca

Associated clinical trials:

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis | NCT00089791

Articles citing this

A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res (2012) 2.43

Low bone mineral density and fractures in stages 3-5 CKD: an updated systematic review and meta-analysis. Osteoporos Int (2014) 1.03

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag (2012) 0.97

A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis (2011) 0.96

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res (2015) 0.95

Denosumab for treatment of immobilization-related hypercalcaemia in a patient with advanced renal failure. Clin Kidney J (2012) 0.92

Treatment of immobilization-related hypercalcaemia with denosumab. Clin Kidney J (2012) 0.92

RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res (2014) 0.85

Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep (2014) 0.81

Chronic kidney disease and the skeleton. Bone Res (2014) 0.79

Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study. BMC Nephrol (2012) 0.79

Metabolomics and Its Application in the Development of Discovering Biomarkers for Osteoporosis Research. Int J Mol Sci (2016) 0.79

Chronic kidney disease and bone metabolism. J Bone Miner Metab (2015) 0.77

Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences. J Bone Oncol (2012) 0.76

Treatment of osteoporosis in renal insufficiency. Clin Rheumatol (2015) 0.76

Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment. J Drug Assess (2012) 0.75

Bone Disease after Kidney Transplantation. Clin J Am Soc Nephrol (2016) 0.75

Update on denosumab treatment in postmenopausal women with osteoporosis. Endocrinol Metab (Seoul) (2015) 0.75

Bisphosphonates for Osteoporosis in Patients with Renal Insufficiency: Pharmacists' Practices and Beliefs. Can J Hosp Pharm (2016) 0.75

Dramatic increase in parathyroid hormone and hypocalcaemia after denosumab in a kidney transplanted patient. Clin Kidney J (2012) 0.75

Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. Biomed Res Int (2017) 0.75

Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone. Int J Nanomedicine (2017) 0.75

Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol (2017) 0.75

Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome. Osteoporos Int (2013) 0.75

Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. Calcif Tissue Int (2017) 0.75

Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency. Support Care Cancer (2014) 0.75

Bone Quality in Chronic Kidney Disease: Definitions and Diagnostics. Curr Osteoporos Rep (2017) 0.75

Positioning novel biologicals in CKD-mineral and bone disorders. J Nephrol (2017) 0.75

Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density. Clin Rheumatol (2016) 0.75

[Pharmaceutical therapy of bone metabolism disorders in chronic kidney disease mineral bone disorder (CKD-MBD) with special respect to antiresorptive substances]. Z Rheumatol (2014) 0.75

Breast cancer and bone metastases: a call for appropriate treatment. Support Care Cancer (2016) 0.75

Articles by these authors

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27

Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med (2005) 15.30

Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57

A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med (2009) 11.20

Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02

Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83

Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med (2003) 8.87

Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med (2007) 7.60

Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76

Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66

Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med (2006) 6.58

Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47

Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med (2010) 6.13

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76

Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA (2005) 5.46

Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med (2010) 4.24

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15

Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med (2004) 3.93

Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology (2004) 3.89

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int (2003) 3.75

Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab (2008) 3.67

Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40

Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res (2004) 3.37

Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol (2005) 3.28

Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust (2012) 3.14

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01

Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87

The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis (2004) 2.83

Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet (2011) 2.73

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract (2004) 2.69

Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res (2007) 2.68

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med (2005) 2.60

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53

Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. J Bone Miner Res (2015) 2.52

Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA (2008) 2.52

Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmenopausal women: a randomized controlled pilot study. J Bone Miner Res (2003) 2.47

Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res (2008) 2.44

Is high dose vitamin D harmful? Calcif Tissue Int (2012) 2.43

Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone (2008) 2.37

Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol (2007) 2.31

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29

Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol (2011) 2.28

Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24

Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res (2009) 2.20

Population genomics in a disease targeted primary cell model. Genome Res (2009) 2.20

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 2.16

Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol (2009) 2.11

Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med (2008) 2.11

Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis (2008) 2.10

Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res (2011) 2.07

Comparative bone status assessment by dual energy X-ray absorptiometry, peripheral quantitative computed tomography and quantitative ultrasound in adolescents and young adults with cystic fibrosis. J Cyst Fibros (2011) 2.06

Androgens and bone. Endocr Rev (2004) 2.06

Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04

Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab (2010) 2.01

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98

Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab (2004) 1.96

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res (2010) 1.95

Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone (2007) 1.94

The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol (2006) 1.93

Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol (2006) 1.92

The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92

Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res (2006) 1.91

Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol (2004) 1.91

Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89

Risk of hip fracture among dialysis and renal transplant recipients. JAMA (2002) 1.81

High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol (2011) 1.81

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81

Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol (2007) 1.80

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80

Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin (2008) 1.79

Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2014) 1.78

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res (2008) 1.78

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab (2013) 1.77

COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. Hum Mutat (2011) 1.77

Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res (2004) 1.76

National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom (2008) 1.76

Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol (2007) 1.75

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res (2010) 1.74

The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther (2005) 1.72

Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis (2002) 1.69

Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol (2004) 1.68

Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). Diabetes Care (2011) 1.67

Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom (2008) 1.66

Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med (2010) 1.66

Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol (2012) 1.65